Cargando…

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

The body of evidence suggesting a causative, initiating role of beta amyloid (Aβ) in the pathogenesis of Alzheimer’s disease (AD) is substantial. Yet, only a few anti-amyloid agents have shown meaningful efficacy in clinical trials. We evaluated the unifying characteristics of anti-amyloid agents wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolar, Martin, Abushakra, Susan, Hey, John A., Porsteinsson, Anton, Sabbagh, Marwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424995/ https://www.ncbi.nlm.nih.gov/pubmed/32787971 http://dx.doi.org/10.1186/s13195-020-00663-w

Ejemplares similares

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
por: Hey, John A., et al.
Publicado: (2018)

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
por: Hey, John A., et al.
Publicado: (2017)

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
por: Honig, Lawrence S., et al.
Publicado: (2023)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline
por: Abushakra, Susan, et al.
Publicado: (2020)

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
por: Söderberg, Linda, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease
por: Lannfelt, Lars, et al.
Publicado: (2014)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
por: Tolar, Martin, et al.
Publicado: (2021)

Topical Insights Into the Post-Approval Controversies of Aducanumab
por: Kumar, Dhiraj, et al.
Publicado: (2021)

How Will Aducanumab Approval Impact AD Research?
por: Weiner, Michael W., et al.
Publicado: (2021)

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
por: Logovinsky, Veronika, et al.
Publicado: (2016)

Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab
por: Chertkow, Howard, et al.
Publicado: (2021)

Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
por: Sabbagh, Marwan Noel, et al.
Publicado: (2020)

Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
por: Bateman, Randall J., et al.
Publicado: (2022)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

HP9800 - HP2401 interface
por: Littlewood, R K
Publicado: (1977)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease
por: Novakovic, Dijana, et al.
Publicado: (2013)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
por: Silvestro, Serena, et al.
Publicado: (2022)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
por: Park, Jong-Chan, et al.
Publicado: (2021)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Novel Therapeutics in Alzheimer's Disease
por: Sabbagh, Marwan, et al.
Publicado: (2012)

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
por: Klein, Gregory, et al.
Publicado: (2019)

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease
por: Satlin, Andrew, et al.
Publicado: (2016)

Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease
por: Zissimopoulos, Julie, et al.
Publicado: (2022)

AlzPharm: integration of neurodegeneration data using RDF
por: Lam, Hugo YK, et al.
Publicado: (2007)

A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2017)

In silico exploration of amyloid‐related imaging abnormalities in the gantenerumab open‐label extension trials using a semi‐mechanistic model
por: Aldea, Roxana, et al.
Publicado: (2022)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
por: Ostrowitzki, Susanne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ma57ocf8koei94eeeptq1sqopb